Trifluoperazine Inhibits Mesangial Cell Proliferation by Arresting Cell Cycle-Dependent Mechanisms

Baodong Wang
Xiaoshuang Zhou
Yanqin Wang
Rongshan Li

Background:
It has been reported that trifluoperazine (TFP) inhibits proliferation of cancer cells, however, the effects of TFP in renal proliferation diseases are still unclear. This study examined the effects of TFP on proliferation of human renal mesangial cells and analyzed the underlying mechanisms.

Material/Methods:
Cell proliferation in vivo was determined by HE staining, immunohistochemistry of proliferating cell nuclear antigen (PCNA), and Western blot analysis (Ki-67 and PCNA). Effects of different TFP concentrations and treatment duration on cell proliferation and cell cycle were analyzed using the MTT assay and flow cytometry. Expression of G0/G1 phase cell cycle-related proteins and TFP-induced MAPK and PI3K/AKT signaling pathways was estimated with Western blot analysis.

Results:
Our findings suggest that TFP inhibits cell proliferation in a dose- and time-dependent manner and decreased PCNA and Ki-67 levels in lupus MRL/lpr mice. TFP arrested the cell cycle in the G0/G1 phase, down-regulating cyclin D1, CDK2, and CDK4, and up-regulating p21 expression in a dose-dependent manner. In addition, TFP inhibited p-AKT and p-JNK, possibly by suppressing the activation of PI3K/AKT and JNK/MAPK signaling pathways. TFP treatment remarkably reduced the levels of serum creatinine (Cr) in lupus mice.

Conclusions:
TFP exhibits inhibitory activity against mesangial cells in vivo and in vitro, which is associated with G1 cell cycle arrest by inactivation of PI3K/AKT and JNK/MAPK signaling pathways. These results suggest the potential of TFP in treatment of mesangial proliferative diseases.

MeSH Keywords:
Cell Cycle • Mesangial Cells • Trifluoperazine

Abbreviations:
MsPGN – mesangial proliferative glomerulonephritis; TFP – trifluoperazine; PCNA – proliferating cell nuclear antigen; Cr – creatinine

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/902522
Background

Mesangial cells (MC) are specialized cells that form the glomerular mesangium and, combined with the mesangial matrix, shape the vascular pole of the glomerulus. Mesangial cells play an essential role in many aspects, for example, formation of capillary loops during development, contraction to regulate capillary flow, and removal of macromolecules [1–3], but the severe proliferation of MC causes functional damage of the kidneys.

Mesangial proliferative glomerulonephritis (MsPGN) is characterized by MC proliferation and various degrees of extracellular matrix (ECM) thickening [4,5]. Immunologically, MsPGN can be an IgA- or non-IgA nephropathy. Inhibition of MC proliferation was shown to slow the progression of MsPGN [6,7].

MRL/lpr lupus mice are a well-known pathological model of mesangial cell proliferative nephropathy [8–10]. Due to mutations of the lpr gene, MRL/lpr mice do not produce functional Fas receptor, which allows autoreactive T cells to escape negative selection in the thymus and be released into the peripheral organs, causing spontaneous lupus nephritis (LN) in animals at the age of approximately 24 weeks. Renal pathology of LN involves MC proliferation and thickening of the mesangial matrix [11]. As high concentrations of fetal bovine serum (FBS) stimulate abnormal proliferation of mesangial cells in vitro, mesangial cells stimulated by 20% FBS were used in this study [12].

The role of cell cycle regulation in MsPGN pathogenesis is widely recognized in cell and in vitro studies. In cultured human MC, expression of cyclin-dependent kinases 2 and 4 (CDK2 and CDK4) and cyclins A, D1, and E was up-regulated by stimulation with different mitogens (6–8), whereas opposing p27\(^{kip1}\) and p21\(^{waf1}\) were down-regulated [13–15]. Ke et al. [16] reported that morin inhibits MC proliferation and ECM accumulation in vivo in rats, by promoting the activation of p27\(^{kip1}\) and p21\(^{waf1}\) and thus has potential use in the treatment of MC proliferative nephropathy. Tian et al. [17] reported that early application of low-dose rapamycin, an mTOR inhibitor, slows the progression of MsPGN and protects renal function by arresting the cell cycle in rats. These data suggest that modulating cell cycle regulation in glomerular MC may slow the progression of MsPGN.

Trifluoperazine (TFP) is a calmodulin inhibitor and a classic antipsychotic drug. Calmodulin is involved in cellular proliferation, inflammation, neurodegeneration, and other pathological processes. TFP was shown to suppress proliferation of breast cancer, fibrosarcoma HT1080, leukemia, and human A549 lung adenocarcinoma cells, by regulating different signaling pathways [18–22]. However, the role of TFP in MC is unclear.

The present study was planned to investigate the effects of TFP on cell proliferation and cell cycle progression in human mesangial cell line in vivo and in vitro.

Material and Methods

Animals

Young (6–7-week-old) female C57BL/6 mice weighing 20±5 g were purchased from the Experimental Animal Center of Shanxi Medical University (Taiyuan, China). Female MRL/lpr LN mice were purchased from the Model Animal Institute of Nanjing University (induced from Jackson Laboratories, USA). The mice were housed under controlled environmental conditions (temperature 22°C, 12-h light-dark cycle), given free access to water, and fed a standard laboratory diet. The animals were active and had glossy hair before the start of the experiments. The study was conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of Shanxi Medical University. Twenty-four female mice were randomly divided into 3 groups: control group, LN group, and LN+TFP group. Mice in the LN+TFP group were intraperitoneally injected with TFP (20 mg/kg·d, 12 weeks, Sigma, St. Louis, MO, USA), whereas the LN group received saline for 12 weeks. The animals were sacrificed 12 h after the last injection. Serum was collected by centrifuging at 5000 rpm for 15 min at 4°C, and stored at −20°C for determining CRE levels. Renal tissues were obtained and kept in 10% neutral-buffered formalin and embedded in paraffin for histopathological and immunohistochemistry (IHC) analysis. Additional renal samples were immediately frozen in liquid nitrogen and stored at −80°C until analysis.

PCNA immunohistochemistry

Renal tissues were fixed in formalin and embedded with paraffin. Tissue sections were deparaffinized in xylene. Unspecific staining was blocked with 1.5% standard goat serum for 20 min before incubation with 1: 100 diluted primary PCNA antibody overnight at 4°C. Sections incubated with PBS were used as negative control. The samples were incubated with a biotinylated secondary antibody for 1 h at room temperature. Glomeruli of mice (10 per mouse) were blindly assessed at each time point using high-power light microscopy (×400). PCNA relative density was calculated as the ratio of PCNA-positive cells to total glomerular cells.

Cell culture and treatments

The human mesangial cell line T-SV40 was donated by Dr Li Xuewang at Union Medical College Hospital (Beijing, China) and grown in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% FBS (HyClone) at 37°C with 5% CO\(_2\).
Approximately 70%-confluent cells were incubated in serum-free medium for 24 h and treated with 10% and 20% FBS as control and model groups, respectively. Different concentrations of TFP were added to the corresponding groups.

3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay

Cell proliferation was analyzed using the MTT assay. The cells were grown in 96-well plates at the density of 10⁵ cells/well and treated with 10% or 20% FBS and different concentrations of TFP (0, 5, 10, 20, and 30 µmol/L) for 24 h. Following treatment, the cells were incubated with 15 µL MTT (0.5%, Sigma) for 3 h at 37°C (n=6 per group). The medium was removed and 150 µL of dimethyl sulfoxide (Sigma) was added to each sample. A microplate reader (Bio-Rad Model 550, Hercules, CA, USA) was used to determine absorbance at 560 nm.

Flow cytometry analysis

Effects of TFP on the cell cycle were analyzed using flow cytometry. The cells (6×10⁵ cells/well) were seeded in 6-well plates and cultured without FBS for 24 h to achieve cell synchronization. Next, the cells were treated with 10% or 20% FBS and TFP (0, 5, 10, and 20 µmol/L) for 24 h. After washing, the cells were fixed in 75% at 4°C overnight. The fixed cells were collected and stained with propidium iodide (50 µg/ml; Sigma) containing RNase (50 µg/ml). An FC500 flow cytometer (Coulter, Beckman, Palo Alto, CA, USA) was used to determine the proportion of cells in different phases of the cell cycle (G1, S, and G2/M).

Western blot analysis

The cells were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotech, Jiangsu, China), and centrifuged at 12000 x g for 45 min at 4°C. After harvesting the supernatant, protein concentration was determined using the BCA assay kit KeyGEN (Beyotime Biotech). Samples containing 60 µg of protein were resolved on 12% SDS-PAGE electrophoresis and transferred to nitrocellulose membrane (Whatman International Ltd., Germany). After blocking for 1 h, the membranes were incubated with the following primary antibodies overnight at 4°C: Ki-67 (H-300), PCNA (FL-261), cyclin E (M20), cyclin D1 (H-295), p27 (C-19), p21 (C-19), CDK2 (D-12), CDK4 (C-22), CDK6 (C-21), p-ERK 1/2 (E-4), ERK 1/2 (H-72), p-JNK (G-7), JNK (D-2), p-AKT/Thr308 (p-AKT), AKT, and β-actin (C4). Dilution 1: 200 (Santa Cruz Biotechnology) antibody. After being washed 3 times with TBST buffer, the membranes were incubated with corresponding horseradish peroxidase-conjugated secondary antibodies for 1.5 h at room temperature and analyzed using the Quantity One analysis system (Bio-Rad, Hercules, CA, USA).

Measurement of renal function

Creatinine (Cr), a key renal function marker, was determined with commercially available kits according to the manufacturer’s instructions (Shanghai Elisa Biotech Co., Ltd.). The observation absorbance of Cr was read at 450 nm.

Statistical analyses

Statistical analyses were performed using SPSS 19.0 (IBM, Armonk, NY, USA). The values are expressed as the means ±SD. The differences between the 2 groups were determined by the two-tailed Student’s t-test. A p value < 0.05 was considered statistically significant.

Results

TFP inhibits cellular proliferation in glomeruli of LN mice

Hematoxylin and eosin (HE) staining indicated diffuse proliferation of mesangial cells and matrix in the glomeruli of LN mice, compared to control, which decreased after 3-month treatment with TFP (Figure 1A). Proliferating cell nuclear antigen (PCNA) immunohistochemistry confirmed these findings (Figure 1B). In addition, Western blotting showed that TFP significantly decreased the expression of Ki-67 and PCNA in LN mice (Figure 1C).

TFP reduces MC proliferation in vitro

The MTT assay showed time- and dose-dependent inhibition of MC proliferation by TFP (Figure 2A). Meanwhile, the inhibitive rate of MC was correspondingly added the increase of the concentration of TFP (Figure 2B).

TFP arrests the MC cycle in the G1 phase

After 24-h treatment with TFP in 20% FBS, the number of MCs in G1 and S phases was significantly increased and decreased, respectively, compared to the 20% FBS group. The effect was dependent on the dose of TFP (Figure 3).

Effects of TFP on expression of cell cycle-related proteins

Western blot analysis was used to confirm the effects of TFP on expression of cell cycle-related proteins. Compared to control (10% FBS), high concentration (20%) of FBS markedly increased the expression of cyclin D1, CDK2, CDK4, and CDK6 and decreased the expression of p21 and p27. TFP (5, 10, and 20 µM) pretreatment decreased the levels of cyclin D1, CDK2, and CDK4 and increased p21 expression, in a dose-dependent manner (Figure 4A). CDK6, cyclin E, and p27 expression was...
Figure 1. TFP inhibits cellular proliferation in glomeruli of LN mice. TFP inhibited cellular proliferation in LN mice. (A) HE staining (400× magnification. Scale bar, 50 μm); (B) PCNA immunohistochemistry (400× magnification. Scale bar, 50 μm); (C) Expression of PCNA and Ki-67 was analyzed with Western blotting. (*p<0.05 vs. N, **p<0.01 vs. N, #p<0.05 vs. LN, ##p<0.01 vs. LN; N – control; LN – lupus nephritis groups; LN+TFP – TFP-treated lupus nephritis groups.)

Figure 2. TFP reduces MC proliferation in vitro. TFP reduced MC proliferation. Quiescent MCs were treated with 10 and 20% FBS in the absence or presence of TFP (5, 10, 15, 20, and 30 μmol/L). Cell viability was assessed using the MTT assay after 12, 24, and 36 h. Data are presented as means ±SD values of 3 independent experiments. (*p<0.05 vs. control, **p<0.01 vs. control, #p<0.05 vs. 20% FBS group, **p<0.01 vs. 20% FBS group, ***p<0.001 vs. 20% FBS group).
not affected by TFP. These results were further validated by Western blot analysis in LN mice (Figure 4B).

**TFP suppressed p-AKT and p-JNK without affecting p-ERK1/2**

Western blot analysis showed that 20% FBS activated extra-cellular signal-regulated kinase (ERK)-MAPK, c-Jun N-terminal kinase (JNK)-MAPK, and PI3K/AKT signaling pathways, compared to control (10% FBS). TFP pretreatment significantly and dose-dependently decreased p-JNK and p-AKT levels in 20% FBS-cultured MCs, with no observable change in p-ERK levels, compared to the 20% FBS group (Figure 5). These results suggest that TFP inhibits JNK-MAPK and PI3K/AKT signaling pathways without affecting ERK-MAPK.

**The effect of TFP in renal function in LN mice**

The effect of TFP on renal function in LN mice was investigated. The level of serum Cr was markedly increased in the LN
group compared to the control groups. However, serum Cr was significantly decreased in TFP-treated LN mice (Figure 6). The data demonstrate that TFP improved renal function in LN mice.

**Discussion**

MC proliferation is a key feature of glomerular diseases, including IgA nephropathy, lupus nephritis, and diabetic nephropathy. In experimental animal models of nephritis, MCs are used as target cells of immune injury because stimulation-induced MC proliferation accelerates kidney damage and promotes glomerulosclerosis because of the release of inflammatory factors and ECM components. Therefore, inhibition of MC proliferation has become an important treatment approach for proliferative glomerular diseases. As TFP was recently shown to inhibit proliferation of cancer cells, this study focused on the effects of TFP on MC proliferation, using MC cells in 20% FBS and LN mice.
In vitro, TFP inhibited MC proliferation, as shown by the MTT assay. TFP effects on the cell cycle were analyzed using flow cytometry. In TFP-treated cells, prolonged G$_1$/G$_0$ phase and shortened S phase were observed, indicating that TFP extended the G$_1$ phase and inhibited cell proliferation. These results are consistent with previous studies on TFP in other tissues and proliferative diseases [23,24].

The 4 stages of the cell cycle – G$_0$/G$_1$, S, G$_2$, and M – are regulated by growth factors, oncogenic stimulation, or regulatory units such as cyclin/CDK complexes [25,26]. As flow cytometry indicated that TFP mainly affected MCs in the G$_1$/G$_0$ phase, we focused on G$_1$/G$_0$ regulators. Cyclins D and E, together with CDK2, CDK4, or CDK6, promote progression of cells from the G$_1$ to the G$_2$ phase, whereas p21 and p27 have an opposite effect. Our results showed that upon stimulation with 20% FBS, expression of cyclins D and E, and CDKs 2, 4, or 6 in MCs was increased, whereas expression of p27 and p21 was significantly inhibited, in agreement with previous work [12]. TFP treatment decreased cyclin D1, CDK2, and CDK4 expression, whereas p21 expression was increased in a dose-dependent manner. No changes in the protein levels of cyclin E, CDK6, and p27 were observed. In vivo, Western blotting indicated that cyclin D1, CDK2, and CDK4 expression levels were up-regulated in LN mice, whereas p21 expression was decreased, compared to control. For cyclin D1, CDK2, and p21, the trend was reversed after 12 weeks of TFP treatment. These results indicate that, in proliferating MCs, TFP down-regulates the expression of cyclin D1, CDK2, and CDK4 and up-regulates p21 expression, in a dose-dependent manner.

MAPK and PI3K/AKT signaling pathways participate in regulation of cell apoptosis and proliferation. The MAPK family of serine/threonine kinases consists of 3 subtypes: ERK, JNK, and p38MAPK. ERK is activated by growth factors and is associated with differentiation and cell death. In contrast, JNK responds to environmental stress, pro-cytokines, and mitogens [27,28]. ERK and JNK are activated during abnormal proliferation of mesangial cells, in vivo and in vitro, affecting cell cycle progression [17,29]. AKT is a promoter of cell proliferation and survival and is overexpressed in tumors, suggesting that activation of AKT may promote abnormal proliferation of cells [30,31]. Previous studies suggest that inactivation of AKT decreases the expression of cyclin D1, CDK2, and CDK4.
inhibiting G1/S cell cycle progression [26,32]. In this study, ERK, JNK, and AKT were activated by 20% FBS. TFP treatment inactivated AKT and JNK in MCs, consistent with TFP-mediated suppression of cyclin D1 and CDK2 expression and up-regulation of p21 expression. ERK levels were not affected by TFP treatment. Therefore, we conclude that TFP arrests cell cycle progression in the G1/G0 phase by down-regulating phosphorylated AKT and JNK, and subsequently increasing p21 levels and decreasing cyclin D1, CDK2, and CDK4 expression.

Serum Cr (a blood measurement) is an important indicator of renal health because it is an easily measured byproduct of muscle metabolism that is excreted unchanged by the kidneys. A rise of creatinine in blood always predicts marked damage to functioning nephrons [33]. In our study, the level of serum Cr was associated with markedly increased injury in the LN mice group; however, there was an obviously decrease after TFP treatment TFP (20 mg/kg·d, 12 weeks). These results indicate that TFP slows LN progression in the MRL/lpr mice.

Conclusions

In summary, we demonstrated that TFP exhibits anti-proliferative effects on mesangial cells in vivo and in vitro. TFP inhibited JNK and AKT-mediated signaling pathways, suppressing the expression of cyclin D1, CDK2, and CDK4 complexes, and increasing p21 expression, leading to G1/G0 cell cycle arrest (Figure 7). These findings indicate that TFP is a promising anti-proliferative agent for the treatment of mesangial proliferative glomerulonephritis and related diseases.

Acknowledgments

The authors would like to thank Dr Xuewang Li for providing the human mesangial cells.

Conflicts of Interest

The authors declare no conflict of interest.

References:

1. Takano K, Kawasaki Y, Imaiizumi T et al: Development of glomerular endothelial cells, podocytes and mesangial cells in the human fetus and infant. Tohoku J Exp Med, 2007; 212(1): 81–90.
2. Schlondorff D, Banas B: The mesangial cell revisited: No cell is an island. J Am Soc Nephrol, 2009; 20: 1179–87.
3. Scindia YM, Deshmukh US, Bagavant H: Mesangial pathology in glomerular disease: Targets for therapeutic intervention. Adv Drug Deliv Rev, 2010; 62: 1337–43.
4. Cove-Smith A, Hendry BM: The regulation of mesangial cell proliferation. Nephron Exp Nephrol, 2008; 108: 674–79.
5. Kute VB, Vanikar AV, Shah PR et al: Mesangial proliferative glomerulonephritis with acute tubule interstitial nephritis leading to acute kidney injury in influenza a (h1n1) infection. Indian J Nephrol, 2014; 24: 114–16.
6. Zhou X, Workeneh B, Hu Z, Li R: Effect of immunosuppression on the human mesangial cell cycle. Mol Med Rep, 2015; 11: 910–16.
7. Kitz W, Hahnel B, Hosser H et al: Pathways to recovery and loss of nephrons in anti-thy-1 nephritis. J Am Soc Nephrol, 2003; 14: 1904–26.
8. Lamoureux JL, Watson LC, Cherrier M et al: Reduced receptor editing in lupus-prone mrl/lpr mice. J Exp Med, 2007; 204: 2853–64.
9. Reilly CM, Mishra N, Miller JM et al: Modulation of renal disease in mrl/lpr mice by suberylanilide hydroxamic acid. J Immunol, 2004; 173: 4171–78.
10. Peairs A, Dal R, Gan L et al: Epigallocatechin-3-gallate (egcg) attenuates inflammation in mrl/lpr mouse mesangial cells. Cell Mol Immunol, 2010; 7: 123–32.
11. Matsumoto K, Yoshikai Y, Asano T et al: Defect in negative selection in lpr donor-derived T cells differentiating in non-lpr host thymus. J Exp Med, 1991; 173: 127–36.
12. Chen D, Li Y, Mei Y et al: Mrir-34a regulates mesangial cell proliferation via the pdgfr-beta/raf-mapk signaling pathway. Cell Mol Life Sci, 2014; 71: 4027–42.
13. Shankland SJ, Pippin J, Flanagan M et al: Mesangial cell proliferation mediated by pdgf and bfgf is determined by levels of the cyclin kinase inhibitor p27kip1. Kidney Int, 1997; 51:1088–99.
14. Jiang Y, Cheng DW, Levi E, Singh LP: IGF-1 increases laminin, cyclin d1, and p21cip1 expression in glomerular mesangial cells: An investigation of the intracellular signaling pathway and cell-cycle progression. J Cell Biochem, 2006; 98: 208–20.
15. Qiu LQ, Sinniah R, Hsu SI: Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human ipa nephropathy. Lab Invest, 2004; 84: 1112–25.
16. Ke YQ, Liu C, Hao JB et al: Morin inhibits cell proliferation and fibronectin accumulation in rat glomerular mesangial cells cultured under high glucose condition. Biomed Pharmacother, 2016; 84: 622–27.
17. Tian J, Wang Y, Liu X et al: Rapamycin ameliorates iga nephropathy via cell cycle-dependent mechanisms. Exp Biol Med, 2015; 240: 936–45.
18. Gulino A, Barrera G, Vacca A et al: Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antitoxestrogens in mcf-7 human breast cancer cells. Cancer Res, 1986; 46: 6274–78.
19. Shin SY, Kim SY, Kim JH et al: Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of elk-1 in human fibrosarcoma h1080 cells. J Biol Chem, 2001; 276: 7797–805.
20. Hail WN, Grais L, Benz C, Cadman EC: Inhibition of growth of leukemic cells by inhibitors of calmodulin: Phenothiazines and melittin. Cancer Chemother Pharmacol, 1985; 14: 202–5.
21. Chen QY, Wu LJ, Wu YQ et al: Molecular mechanism of trifluoperazine induces apoptosis in human a549 lung adenocarcinoma cells. Mol Med Rep, 2009 ;2: 811–17.
22. Polischouk AG, Holgersson A, Zong D et al: The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death. Mol Cancer Ther, 2007; 6: 2303–9.
23. Singh A, Sharma S, Khuller GK: Camp regulates vegetative growth and cell cycle in candida albicans. Mol Cell Biochem, 2007; 304: 331–41.
24. Singh J, Chatterjee S: Cell cycle dependent variation of calmodulin in tetrahymena. Cytobios, 1988; 55: 95–103.
25. Hilakivi-Clarke L, Wang C, Kalil M et al: Nutritional modulation of the cell cycle and breast cancer. Endocr Relat Cancer, 2004; 11: 603–22

26. Li T, Zhao X, Mo Z et al: Formononetin promotes cell cycle arrest via downregulation of akt/cyclin d1/cdk4 in human prostate cancer cells. Cell Physiol Biochem, 2014; 34: 1351–58

27. Park HJ, Lee HJ, Choi MS et al: Jnk pathway is involved in the inhibition of inflammatory target gene expression and nf-kappab activation by melitin. J Inflamm (Lond), 2008; 5: 7

28. Nakata K, Suzuki Y, Inoue T et al: Deficiency of shp1 leads to sustained and increased erk activation in mast cells, thereby inhibiting il-3-dependent proliferation and cell death. Mol Immunol, 2011; 48: 472–80

29. Goruppi S, Bonventre JV, Kyriakis JM: Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J, 2002; 21: 5427–36

30. Rodriguez-Barbero A, Dorado F, Velasco S et al: Tgf-beta1 induces cox-2 expression and pge2 synthesis through mapk and pi3k pathways in human mesangial cells. Kidney Int, 2006; 70: 901–9

31. Mitchell D, Rodgers K, Hanly J et al: Lipoxins inhibit akt/pkb activation and cell cycle progression in human mesangial cells. Am J Pathol, 2004; 164: 937–46

32. Guo D, Ye J, Dai J et al: Notch-1 regulates akt signaling pathway and the expression of cell cycle regulatory proteins cyclin d1, cdk2 and p21 in t-ALL cell lines. Leuk Res, 2009; 33: 678–85

33. Saratlija Novakovic Z, Glavina Durdov M et al: The interstitial expression of alpha-smooth muscle actin in glomerulonephritis is associated with renal function. Med Sci Monit, 2012; 18(4): CR235–40